Can better support keep people on HIV prevention? massive malawi trial aims to find out
NCT ID NCT07221747
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This large study in Malawi will test whether extra support—like better communication with providers, peer counselors, and earlier clinic hours—helps people at high risk for HIV stay on their prevention medication. It includes both daily pills and a new long-acting injectable. Nearly 10,000 participants will be followed to see if these strategies improve continuation of PrEP.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORAL PRE-EXPOSURE PROPHYLAXIS (PREP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Community Health Science Unit
RECRUITINGLilongwe, Malawi
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Long-acting injectable cabotegravir and oral PrEP (tenofovir-based)
What this could lead to
If successful, this could show practical ways to help more people stay on HIV prevention, reducing new infections in high-risk groups.
What could go wrong
This is a behavioral study, not testing a new drug. Results may not apply outside Malawi, and adherence strategies may not work as well in other settings.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.